Guggenheim analyst John Heinbockel maintained a Buy rating on Dollar Tree (DLTR – Research Report) today and set a price target of $175.00. The company’s shares closed last Thursday at $148.01, close to its 52-week high of $149.37.
Heinbockel has an average return of 16.6% when recommending Dollar Tree.
According to TipRanks.com, Heinbockel is ranked #740 out of 7782 analysts.
Dollar Tree has an analyst consensus of Strong Buy, with a price target consensus of $168.78, implying a 18.9% upside from current levels. In a report issued on February 28, BMO Capital also upgraded the stock to Buy with a $170.00 price target.
Based on Dollar Tree’s latest earnings release for the quarter ending October 31, the company reported a quarterly revenue of $6.42 billion and net profit of $217 million. In comparison, last year the company earned revenue of $6.18 billion and had a net profit of $330 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dollar Tree, Inc. is a discount variety retail store operator that sells items for $1 or less. The company operates over 15,000 stores in the United States and Canada under the Dollar Tree and Family Dollar brands. It offers a wide range of quality everyday general merchandise in several categories, including candy and food, housewares, seasonal goods, health and beauty care, stationery, books, personal accessories, toys, gifts, party goods, and other consumer items.
Read More on DLTR:
- Analysts Offer Insights on Healthcare Companies: Petiq (PETQ) and Bright Health Group (BHG)
- Analysts Are Neutral on These Services Stocks: Terminix Global Holdings (TMX), Paysafe (PSFE)
- Analysts Conflicted on These Financial Names: Principal Financial (PFG), Realty Income (O) and Reinsurance Group (RGA)
- Analysts Conflicted on These Technology Names: First Solar (FSLR), IPG Photonics (IPGP) and Snowflake (SNOW)
- OrthoPediatrics (KIDS) Gets a Buy Rating from Needham